Palatability and oral cavity tolerability of THCCBD oromucosal spray and possible improvement measures in multiple sclerosis patients with resistant spasticity a pilot study.
Complaints about Δ Patients with multiple sclerosis spasticity (n 52) at six sites in Italy who were receiving THCCBD oromucosal spray and had associated oral mucosal effects were randomized into Group A (chewing gum n 15) Group B (cold bottle n 20) and Group C (cold bottle chewing gum n 17). Taste perception in patients receiving chewing gum ± cold bottle intervention (Groups A and C combined) was significantly (p 0.0001) improved from baseline to week 4 while maintaining spasticity control. Patient comfort, satisfaction and treatment adherence may benefit from these interventions.